Skip to content

Climb Bio, Inc. CLYM Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Amgen logo
AmgenAMGN
-$959M-9.7%
Vera Therapeutics logo
Vera TherapeuticsVERA
-$437K+90.9%
Kyverna Therapeutics, Inc. logo
Kyverna Therapeutics, Inc.KYTX
-$6.88M-281%
Jade Biosciences, Inc. Common Stock logo
Jade Biosciences, Inc. Common StockJBIO
$5.77M+396%
Shattuck Labs, Inc. logo
Shattuck Labs, Inc.STTK
-$1.96M-173%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
-$4M-330%

Other financials

Income statement

See full
Operating income-$15.2M+33.9%
Net income-$13.7M+34.0%
EPS (diluted)-$0.20+35.5%

Balance sheet

See full
Cash & equivalents$8.4M-71.2%
Total debt$479.0K+1.1%
Total equity$148.1M-23.4%
Total assets$152.4M-24.1%

Cash flow

See full
Operating cash flow-$14.4M+6.8%
CapEx$109.0K
Free cash flow-$15.6M-183%

Valuation

See full
Market cap$724.95M+787%
Enterprise value$717.07M+1,247%

Returns & leverage

See full
Return on equity-30.9%-10.3pp
Debt / equity0.0×
Current ratio27.9×+13.6×

Where this comes from

Reported directly by Climb Bio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: Climb Bio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Climb Bio, Inc.'s change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Climb Bio, Inc.'s change in accrued liabilities?
Climb Bio, Inc. (CLYM) reported change in accrued liabilities of -$1.53M in Q1 2026.
How has Climb Bio, Inc.'s change in accrued liabilities changed year-over-year?
Climb Bio, Inc.'s change in accrued liabilities decreased by 175.3% year-over-year, from $2.04M to -$1.53M.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.